21 September 2006
Interim Results for the six months ended 30 June 2006
Futura Medical plc (AIM: FUM), the pharmaceutical and medical device group, is pleased to announce its Interim Results for the six months ended 30 June 2006.
Operational Highlights in the year to date
- MED2002: global development agreement with GSK
- CSD500: regulatory approval on track
- FLD500: dossier submission scheduled for 2007
- DCF100: excellent permeation study results
Financial Highlights
- Pre-tax loss of £1.0 million for the six months ended 30 June 2006 (H1 2005: pre-tax loss of £1.0 million - as restated)
- Cash of £1.4 million at 30 June 2006 (30 June 2005: £2.7 million)
- Successful placing raised £3.4 million net in July 2006
Commenting on the results James Barder, Futura's Chief Executive, said: "The period under review, and post the period end, has been transformational for the Company in that, with GSK and SSL, we now have routes to market with blue chip partners for all of our three leading products. In addition we have progressed our new product portfolio by leveraging our intellectual property portfolio to create value for shareholders."
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.co.uk
www.futuramedical.co.uk
For any media enquiries please contact:
Buchanan Communications Limited
Mark Court
+44 (0) 20 7466 5000
markc@buchanan.uk.com
www.buchanan.uk.com